Reason for request
Reassessment of medicines containing methylphenidate in attention deficit hyperactivity disorder in response to the instruction from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of QUASYM LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years old and over when psychological, educational and social management alone prove insufficient. |
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
U2Ecnd2Scp68ecHy
Listen
